Grant: Engage Grants Program
University of Alberta
$25,000.00
Low-intensity pulsed ultrasound for enhancing vaccine production
FY 2012-13
Summary
Akshaya Bio Inc. is a biotechnology company located in Edmonton, Alberta, Canada. The company develops therapeutic products based on three technology platforms, Chimigen, targeted-autothrombogenic cancer therapy (T-ACT), and antibody-based immunotherapy (AIT). The Chimigen platform is used to produce Hepatitis B vaccine candidates such as CHB111, which has passed Phase I clinical trial for treating chronic hepatitis B infection. With ever increasing demands for the CHB111 vaccine, Akshaya Bio Inc. is looking for new technologies to increase CHB111 vaccine production while reducing manufacturing cost. Meanwhile Dr. Chen's research group at the University of Alberta has developed a technological platform to deliver low-intensity pulsed ultrasound (LIPUS). This ultrasound technology has been proven to increase wide varieties of tissue and cell growth. The stimulation of dental tissue formation using LIPUS has been widely reported including listed as one of the major medical breakthroughs in Canada by Readers' Digest in 2008, and covered by ""Global and Mail"" front page in 2008. The US patent of LIPUS for intraoral use has been granted and was licensed by a Canadian company for commercialization. Based on the success of LIPUS technology, Dr. Chen has further explored the LIPUS technology to be used in stem cell and monoclonal antibody (mAb) growth. The results show at least 30% stem cell growth and 60% IgGmAb growth.
Based on the pervious success of LIPUS device, we hypothesize that ultrasound technology can greatly increase vaccine production thus reducing its manufacturing cost. In this proposal, we request NSERC funding support to engage Akshaya Bio Inc. to jointly develop the technology. The project is very meaningful for hepatitis patients worldwide, especially those in developing countries.
Program
Engage Grants Program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
433957-2012
Name nom
Chen, Jie
Department département
Electrical and Computer Engineering
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
2524
Research subject group en
Electrical and electronic engineering
Research subject group fr
Génie électrique et électronique
Research subject en
Ultrasonic/ferroelectric devices and applications
Research subject fr
Applications et dispositifs ultrasoniques et ferroélectriques
Partie
1
Nb partie
1
Application title
Low-intensity pulsed ultrasound for enhancing vaccine production
Keyword
NSERC
Application summary
Akshaya Bio Inc. is a biotechnology company located in Edmonton, Alberta, Canada. The company develops therapeutic products based on three technology platforms, Chimigen, targeted-autothrombogenic cancer therapy (T-ACT), and antibody-based immunotherapy (AIT). The Chimigen platform is used to produce Hepatitis B vaccine candidates such as CHB111, which has passed Phase I clinical trial for treating chronic hepatitis B infection. With ever increasing demands for the CHB111 vaccine, Akshaya Bio Inc. is looking for new technologies to increase CHB111 vaccine production while reducing manufacturing cost. Meanwhile Dr. Chen's research group at the University of Alberta has developed a technological platform to deliver low-intensity pulsed ultrasound (LIPUS). This ultrasound technology has been proven to increase wide varieties of tissue and cell growth. The stimulation of dental tissue formation using LIPUS has been widely reported including listed as one of the major medical breakthroughs in Canada by Readers' Digest in 2008, and covered by ""Global and Mail"" front page in 2008. The US patent of LIPUS for intraoral use has been granted and was licensed by a Canadian company for commercialization. Based on the success of LIPUS technology, Dr. Chen has further explored the LIPUS technology to be used in stem cell and monoclonal antibody (mAb) growth. The results show at least 30% stem cell growth and 60% IgGmAb growth.
Based on the pervious success of LIPUS device, we hypothesize that ultrasound technology can greatly increase vaccine production thus reducing its manufacturing cost. In this proposal, we request NSERC funding support to engage Akshaya Bio Inc. to jointly develop the technology. The project is very meaningful for hepatitis patients worldwide, especially those in developing countries.